Diabetes in Pregnancy

Diabetes complicating pregnancy is among the most heavily examined "high-risk pregnancy" topics in NEET PG, because the diagnostic cut-offs are precise, the maternal–fetal complication chain is logical, and management questions reward clear thinking. This note covers gestational diabetes mellitus (GDM) and pregestational (overt) diabetes — classification, screening, complications, glycaemic targets, and the drug of choice.

Definitions & Classification

Two clinically distinct entities exist:

• Pregestational (overt) diabetes — Type 1 or Type 2 diabetes diagnosed before pregnancy, or diabetes-range hyperglycaemia detected for the first time in early pregnancy (e.g. fasting ≥126 mg/dL or HbA1c ≥6.5% at booking). These women carry the highest risk of congenital malformations.
• Gestational diabetes mellitus (GDM) — carbohydrate intolerance with onset or first recognition during pregnancy (classically second/third trimester), where pre-existing diabetes has been excluded. GDM reflects the diabetogenic stress of pregnancy unmasking limited beta-cell reserve.

High-yield: Hyperglycaemia detected at the first antenatal visit meeting non-pregnant diabetes criteria is labelled overt diabetes, NOT GDM. Only hyperglycaemia below those thresholds, or detected later, is GDM.

Priscilla White Classification

The classic eponymous system grading pregestational diabetes by age of onset, duration, and end-organ damage — repeatedly asked.

Class	Defining feature
A1	GDM controlled by diet alone
A2	GDM requiring insulin/medication
B	Onset age ≥20 yr and duration <10 yr
C	Onset 10–19 yr or duration 10–19 yr
D	Onset <10 yr, or duration ≥20 yr, or benign retinopathy
F	Diabetic nephropathy
R	Proliferative retinopathy
H	Ischaemic heart disease
T	Prior renal transplant

High-yield: Mnemonic for the worst classes — Failing kidney (nephropathy), Retina (proliferative), Heart, Transplant. Class F & R carry the gravest prognosis.

Pathophysiology

Pregnancy is inherently diabetogenic. Placental hormones — chiefly human placental lactogen (hPL), along with progesterone, cortisol, prolactin and growth hormone — antagonise insulin, producing progressive insulin resistance that peaks in the third trimester. Women with inadequate beta-cell compensatory reserve develop GDM.

The fetal consequences follow the Pedersen hypothesis:

Maternal hyperglycaemia → glucose crosses placenta freely (insulin does NOT) → fetal hyperglycaemia → fetal islet hyperplasia & hyperinsulinaemia → insulin acts as a fetal growth hormone → macrosomia, organomegaly, and neonatal hypoglycaemia after cord clamping.

This single chain explains nearly every fetal complication and is a favourite vignette skeleton.

High-yield: Insulin does not cross the placenta; glucose does. Fetal hyperinsulinaemia drives macrosomia and causes neonatal hypoglycaemia in the first hours of life once the maternal glucose supply is cut.

Screening & Diagnosis (the most-tested area)

DIPSI (Diabetes in Pregnancy Study Group of India)

The Government of India / FOGSI-endorsed single-step test, designed for the Indian community where fasting is impractical.

• 75 g oral glucose given irrespective of the last meal (non-fasting acceptable).
• Plasma glucose measured at 2 hours.
• 2-h value ≥140 mg/dL = GDM.

2-h plasma glucose (DIPSI)	Interpretation
<140 mg/dL	Normal
140–199 mg/dL	GDM
≥200 mg/dL	Overt diabetes in pregnancy

High-yield: DIPSI is a single-step, non-fasting 75 g test; the diagnostic cut-off is the 2-hour value ≥140 mg/dL. No fasting sample is needed — this convenience is the whole point.

IADPSG / WHO 2013 — 75 g, fasting, one-step

A 75 g OGTT after overnight fasting; any one abnormal value diagnoses GDM ("one-step").

Time	IADPSG cut-off (mg/dL)
Fasting	≥92
1 hour	≥180
2 hours	≥153

Mnemonic for IADPSG values: "92 – 180 – 153".

Carpenter–Coustan (two-step, 100 g)

Used after a positive 50 g glucose challenge screen (≥140 mg/dL). A 100 g OGTT; two or more values must be exceeded.

Time	Carpenter–Coustan (mg/dL)
Fasting	≥95
1 hour	≥180
2 hours	≥155
3 hours	≥140

High-yield: IADPSG/WHO is one-step and needs one abnormal value; Carpenter–Coustan is two-step and needs two abnormal values. Distinguishing the number of required values is a classic trap.

Timing of screening: universal screening at 24–28 weeks. High-risk women (prior GDM, obesity, family history, PCOS, prior macrosomic baby, glycosuria) are screened at the booking visit and re-tested at 24–28 weeks if initially normal.

Clinical Features & Maternal Risks

GDM is often asymptomatic and detected only on screening — hence universal testing. Maternal associations include:

• Polyhydramnios (fetal osmotic diuresis from hyperglycaemia).
• Pre-eclampsia / gestational hypertension (increased risk).
• Recurrent infections — candidiasis, UTI.
• Operative delivery and birth canal trauma due to macrosomia.
• Future risk: ~50% develop Type 2 DM within 5–10 years → mandatory postpartum reclassification.

Fetal & Neonatal Complications (sequence matters)

The examiners love the order of events. Two timelines:

Pregestational (poor periconceptional control) → congenital anomalies, because organogenesis occurs in the first trimester:

• Caudal regression syndrome / sacral agenesis — the most specific (though not most common) anomaly of maternal diabetes.
• Cardiac: transposition of great vessels, VSD, truncus arteriosus.
• Neural tube defects, anencephaly.
• Renal anomalies.

High-yield: Caudal regression syndrome is the anomaly most characteristic/specific of pregestational diabetes; cardiac defects are the most common anomalies overall. First-trimester glycaemic control prevents these — GDM (late onset) does NOT cause congenital anomalies because organogenesis is already complete.

Late effects (GDM and pregestational) → growth and metabolic:

1. Macrosomia (birth weight >4 kg) with disproportionate shoulder/trunk fat →
2. Shoulder dystocia at delivery →
3. Birth injury — Erb's palsy (C5–C6, brachial plexus), clavicle/humerus fracture, perinatal asphyxia.
4. Neonatal hypoglycaemia (commonest neonatal metabolic problem) from carry-over hyperinsulinaemia.
5. Respiratory distress syndrome — fetal hyperinsulinaemia delays surfactant (lecithin) production → RDS even at relatively late gestation.
6. Polycythaemia & hyperviscosity, hyperbilirubinaemia (jaundice), hypocalcaemia & hypomagnesaemia.
7. Unexplained late stillbirth / IUFD — risk rises near term, justifying timed delivery.
8. Cardiomyopathy — hypertrophic, especially septal.

High-yield: Macrosomia → shoulder dystocia → Erb's palsy is the single most repeated vignette chain. The first manoeuvre for shoulder dystocia is McRoberts manoeuvre (hyperflexion of maternal thighs) ± suprapubic pressure — NEVER fundal pressure.

High-yield: In overt/pregestational diabetes with vascular disease (classes F, R), placental insufficiency can instead cause IUGR — so a diabetic mother can have either a large or a growth-restricted baby depending on vasculopathy.

Investigations & Monitoring

• Diagnosis: OGTT as above (investigation of choice for GDM).
• HbA1c — useful in pregestational diabetes for periconceptional risk; HbA1c >6% (some say >6.5–7%) correlates with higher anomaly rates. Less reliable for GDM diagnosis because of altered RBC turnover in pregnancy.
• Fetal surveillance:
  • Detailed anomaly scan at 18–20 weeks; fetal echocardiography (~22 weeks) in pregestational diabetes given cardiac risk.
  • Serial growth scans from the third trimester for macrosomia/polyhydramnios.
  • NST / biophysical profile in the third trimester (weekly from ~32 weeks; earlier if poorly controlled or vasculopathy).
• Maternal: baseline retinal exam and renal function (proteinuria/creatinine) in pregestational diabetes; monitor for pre-eclampsia.

Management & Drug of Choice

Glycaemic targets in pregnancy

Parameter	Target
Fasting / pre-prandial	≤95 mg/dL
1-hour post-prandial	≤140 mg/dL
2-hour post-prandial	≤120 mg/dL
HbA1c	<6% (ideally)

High-yield: Memorise "95 – 140 – 120": fasting ≤95, 1-h PP ≤140, 2-h PP ≤120 mg/dL. These are the universal pregnancy glycaemic goals.

Stepwise approach

Medical nutrition therapy + exercise (2 weeks trial) → if targets not met → start pharmacotherapy → insulin is the drug of choice → intensify, plan fetal surveillance → timed delivery.

• Diet: ~30 kcal/kg/day (adjusted for BMI), carbohydrate ~40–50%, split into 3 meals + snacks. Roughly 70–85% of GDM is controlled by diet/exercise alone (White class A1).
• Insulin — drug of choice. Does not cross the placenta, most physiological, infinitely titratable. A combination of rapid-acting (lispro/aspart) for post-prandial spikes and intermediate (NPH) or long-acting for fasting control is standard. Insulin requirement rises through pregnancy and falls abruptly post-delivery (watch for hypoglycaemia after placental delivery).
• Oral agents: Metformin and glyburide (glibenclamide) are alternatives where insulin is refused/unavailable; metformin is increasingly used but crosses the placenta, and insulin remains the gold standard. Glyburide crosses minimally but is now less favoured.

High-yield: Insulin is the drug of choice in pregnancy because it does not cross the placenta. Metformin crosses the placenta; glyburide minimally so. Avoid older sulfonylureas and most non-insulin agents.

Timing & mode of delivery

• Well-controlled GDM on diet → may go to 39–40 weeks.
• GDM on insulin / pregestational diabetes → deliver around 38–39 weeks (do not routinely exceed 39 wk) to avoid late stillbirth.
• Estimated fetal weight ≥4.5 kg in a diabetic → offer elective caesarean to avoid shoulder dystocia (≥4 kg is the usual cut-off discussed; ≥4.5 kg is the firmer C-section threshold).
• Intrapartum: maintain maternal glucose ~70–110 mg/dL with insulin–dextrose infusion to prevent neonatal hypoglycaemia.

Postpartum

• Insulin requirement plummets immediately; most GDM women need no therapy postpartum.
• Reclassify with a 75 g OGTT at 6–12 weeks postpartum — essential because of high future Type 2 DM risk.
• Encourage breastfeeding (reduces future maternal and offspring diabetes) and lifestyle modification.

Key Differentials & Pitfalls

Scenario	Distinguishing point
Overt vs gestational diabetes	Early/very high values (FPG ≥126, HbA1c ≥6.5%, random ≥200) = overt; later, milder = GDM
GDM polyhydramnios vs other causes	Diabetes is a leading metabolic cause; exclude anencephaly, TOF/duodenal atresia
Macrosomia (diabetes) vs constitutional large baby	Diabetic macrosomia has truncal/shoulder fat → dystocia risk; constitutional is proportionate
Diabetic IUGR	Seen with maternal vasculopathy (class F/R) despite hyperglycaemia

Recently asked / exam angle

• DIPSI cut-off: single-step, non-fasting 75 g, 2-h ≥140 mg/dL — a near-certain factual MCQ.
• IADPSG values 92/180/153 and the "one abnormal value" rule vs Carpenter–Coustan "two values".
• Caudal regression syndrome as the most specific anomaly; cardiac defects as most common.
• Pedersen hypothesis explaining macrosomia & neonatal hypoglycaemia (glucose crosses, insulin does not).
• Vignette: macrosomic baby → shoulder dystocia → McRoberts manoeuvre first; resulting Erb's palsy (C5–C6).
• Insulin as drug of choice; metformin crosses placenta.
• Glycaemic targets 95/140/120.
• Image/clinical: delayed surfactant → neonatal RDS in infant of diabetic mother.
• Postpartum 75 g OGTT at 6 weeks for reclassification.
• White classification matching (Class F = nephropathy, R = retinopathy).

Rapid revision

1. DIPSI: 75 g, non-fasting, 2-h ≥140 mg/dL = GDM; ≥200 = overt diabetes.
2. IADPSG (75 g, fasting): 92 / 180 / 153 — any one value diagnostic.
3. Carpenter–Coustan (100 g): 95/180/155/140 — needs two values.
4. Universal screening at 24–28 weeks; high-risk at booking.
5. Pedersen: maternal hyperglycaemia → fetal hyperinsulinaemia → macrosomia + neonatal hypoglycaemia.
6. Glucose crosses placenta, insulin does NOT.
7. Caudal regression = most specific anomaly; cardiac defects = most common (pregestational only).
8. Fetal chain: macrosomia → shoulder dystocia → Erb's palsy / clavicle fracture; first step = McRoberts.
9. Fetal hyperinsulinaemia delays surfactant → neonatal RDS.
10. Insulin = drug of choice; metformin crosses placenta; glyburide minimal.
11. Targets: fasting ≤95, 1-h ≤140, 2-h ≤120 mg/dL, HbA1c <6%.
12. Deliver insulin-treated/pregestational diabetics by 38–39 wk; EFW ≥4.5 kg → elective LSCS; reclassify with 75 g OGTT at 6–12 weeks postpartum.